Current Use and Trends in Hematopoietic Cell Transplantation in the United States

Biol Blood Marrow Transplant. 2017 Sep;23(9):1417-1421. doi: 10.1016/j.bbmt.2017.05.035. Epub 2017 Jun 9.

Abstract

Hematopoietic Cell Transplantation (HCT) is an established curative treatment for a number of malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. In this report, we provide information about the number of HCT procedures performed in the United States in 2015, and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We show that the number of HCTs performed annually continues to increase, as the indications for HCT, preferred donor sources, and graft-versus-host prophylaxis continue to evolve. We report on general overall survival by indication, by disease status at transplantation, and by transplant type. This report provides a current perspective on transplantation activity in the United States with a focus on recent trends in alternative donors and contemporary transplantation practices.

Keywords: HCT activity; Trends; US.

Publication types

  • Editorial

MeSH terms

  • Adult
  • Alemtuzumab / therapeutic use
  • Antilymphocyte Serum / therapeutic use
  • Calcineurin Inhibitors / therapeutic use
  • Child
  • Graft vs Host Disease / mortality
  • Graft vs Host Disease / prevention & control*
  • Hematologic Neoplasms / immunology
  • Hematologic Neoplasms / mortality
  • Hematologic Neoplasms / pathology
  • Hematologic Neoplasms / therapy*
  • Hematopoietic Stem Cell Transplantation / methods
  • Hematopoietic Stem Cell Transplantation / statistics & numerical data
  • Hematopoietic Stem Cell Transplantation / trends*
  • Hematopoietic Stem Cells / cytology
  • Hematopoietic Stem Cells / immunology
  • Histocompatibility Testing
  • Humans
  • Methotrexate / therapeutic use
  • Myeloablative Agonists / therapeutic use
  • Survival Analysis
  • Tissue Donors / classification
  • Tissue Donors / supply & distribution*
  • Transplantation Conditioning / methods*
  • Transplantation, Autologous
  • Transplantation, Homologous

Substances

  • Antilymphocyte Serum
  • Calcineurin Inhibitors
  • Myeloablative Agonists
  • Alemtuzumab
  • Methotrexate